Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FWBI First Wave BioPharma		$3.28	$2.33 ▼ $60.00	$7.34M	1.28	212,944 shs	56,500 shs
NRBO NeuroBo Pharmaceuticals	$0.70 +1.2%	$0.78	$2.08 ▼ $5.30	$6.03M	-0.26	52,006 shs	34,797 shs
SXTC China SXT Pharmaceuticals	$1.89 +1.6%	$1.80	$0.95 ▼ $11.92	$29.91M	1.11	1.19 million shs	53,178 shs
VLON Vallon Pharmaceuticals	$1.40 +2.9%	$0.67	$0.21 ▼ $12.92	$18.88M	-1.14	5.78 million shs	147,342 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FWBI First Wave BioPharma	0.00%	0.00%	0.00%	0.00%	0.00%
NRBO NeuroBo Pharmaceuticals	+1.16%	-9.68%	+0.14%	-54.84%	-81.77%
SXTC China SXT Pharmaceuticals	0.00%	-7.35%	+21.15%	-31.02%	-78.13%
VLON Vallon Pharmaceuticals	+2.94%	+6.06%	0.00%	-80.00%	-52.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.6594 of 5 stars	0.0	3.0	0.0	0.0	3.1	0.0	0.6
VLON Vallon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
FWBI First Wave BioPharma	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
VLON Vallon Pharmaceuticals	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	$6.54 per share	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	$1.50 per share	N/A
SXTC China SXT Pharmaceuticals	$1.93M	15.50	N/A	N/A	$243.66 per share	0.01
VLON Vallon Pharmaceuticals	$100K	188.75	N/A	N/A	$0.18 per share	7.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FWBI First Wave BioPharma	-$15.80M	N/A	0.00	N/A	N/A	N/A	-102.83%	-22.74%	N/A
NRBO NeuroBo Pharmaceuticals	-$12.47M	N/A	0.00	N/A	N/A	N/A	-189.12%	-122.31%	8/12/2025 (Estimated)
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
VLON Vallon Pharmaceuticals	-$7.02M	-$0.78	N/A	∞	N/A	N/A	-230.48%	-124.89%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FWBI First Wave BioPharma	N/A	N/A	N/A	N/A	N/A
NRBO NeuroBo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VLON Vallon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FWBI First Wave BioPharma	0.40	1.21	1.58
NRBO NeuroBo Pharmaceuticals	N/A	2.41	2.41
SXTC China SXT Pharmaceuticals	0.01	1.40	1.35
VLON Vallon Pharmaceuticals	N/A	2.29	2.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FWBI First Wave BioPharma	12.30%
NRBO NeuroBo Pharmaceuticals	1.37%
SXTC China SXT Pharmaceuticals	5.02%
VLON Vallon Pharmaceuticals	8.74%

Insider Ownership

Company	Insider Ownership
FWBI First Wave BioPharma	0.49%
NRBO NeuroBo Pharmaceuticals	1.05%
SXTC China SXT Pharmaceuticals	3.95%
VLON Vallon Pharmaceuticals	37.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FWBI First Wave BioPharma	9	2.48 million	2.46 million	Not Optionable
NRBO NeuroBo Pharmaceuticals	10	8.62 million	8.53 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	15.83 million	15.20 million	Not Optionable
VLON Vallon Pharmaceuticals	3	13.48 million	8.45 million	Not Optionable

NRBO, FWBI, SXTC, and VLON Headlines

Recent News About These Companies

Questcor Pharmaceuticals,

July 21, 2023 | forbes.com

Vallon Pharmaceuticals' shareholders approve reverse merger with California company

April 20, 2023 | bizjournals.com

Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

April 20, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023

April 12, 2023 | finance.yahoo.com

Lab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for merger

April 7, 2023 | bizjournals.com

Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET

April 4, 2023 | finance.yahoo.com

Vallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 24, 2023 | finanznachrichten.de

Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results

February 24, 2023 | finance.yahoo.com

Is Vallon Pharmaceuticals Inc (VLON) recent surge justified

February 14, 2023 | benzinga.com

Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event

January 11, 2023 | finance.yahoo.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLON

December 27, 2022 | benzinga.com

Vallon rockets as it announces merger with GRI Bio

December 15, 2022 | thepharmaletter.com

Say goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on Nasdaq

December 14, 2022 | endpts.com

Vallon Pharmaceuticals to merge with California biotech firm in 'best path forward'

December 14, 2022 | bizjournals.com

What's Going On With Vallon Pharmaceuticals Stock Today?

December 14, 2022 | msn.com

Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket

December 14, 2022 | benzinga.com

Vallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell Regulators

December 13, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 3, 2022 | finance.yahoo.com

Vallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

July 28, 2022 | finance.yahoo.com

Vallon Pharmaceuticals, Inc. (VLON)

July 20, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRBO, FWBI, SXTC, and VLON Company Descriptions

First Wave BioPharma NASDAQ:FWBI

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.70 +0.01 (+1.16%)

As of 06/18/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.89 +0.03 (+1.61%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.03 (-1.80%)

As of 06/18/2025 07:56 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Vallon Pharmaceuticals NASDAQ:VLON

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time